

# GUFIC BIOSCIENCES LIMITED

Regd. Office : 37, Kamala Bhavan II, S. Nityanand Road, Andheri (East), Mumbai - 400069  
(CIN- L24100MH1984PLC033519)

Website - www.gufic.com, email - info@guficbio.com, Ph-022 67261000, Fax - 022 67261068

(Rs. in Lakhs except EPS)

## Statement of Standalone Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2020

Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31-Dec-20	30-Sep-20	31-Dec-19	31-Dec-20	31-Dec-19	31-Mar-20
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	<b>INCOME</b>						
a	Revenue from operations	14,441.00	12,034.59	9,774.44	31,889.96	27,616.05	35,775.13
b	Other income	59.59	225.24	305.71	383.73	568.93	681.50
	<b>Total Income</b>	<b>14,500.59</b>	<b>12,259.83</b>	<b>10,080.15</b>	<b>32,273.69</b>	<b>28,184.98</b>	<b>36,456.63</b>
2	<b>Expenses</b>						
a	Cost of materials consumed	6,000.86	4,000.65	5,018.53	13,375.46	11,113.30	15,298.25
b	Purchase of stock-in-trade	1,708.81	1,244.96	1,204.11	3,371.37	3,812.42	3,722.41
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	501.42	1,094.46	(1,423.26)	751.51	(1,215.91)	(1,272.93)
d	Employee benefits expense	1,579.68	1,439.09	1,270.99	4,145.85	3,931.66	5,157.07
e	Finance cost	367.64	338.91	345.32	1,028.82	972.79	1,271.83
f	Depreciation and amortisation expense	322.25	247.96	211.29	798.58	596.35	835.00
g	Other expenses	2,203.15	1,692.94	2,511.22	5,295.46	6,548.53	8,411.99
	<b>Total Expenses</b>	<b>12,683.81</b>	<b>10,058.97</b>	<b>9,138.20</b>	<b>28,767.05</b>	<b>25,759.14</b>	<b>33,423.62</b>
3	Total Profit / (Loss) before exceptional items and tax (1-2)	1,816.78	2,200.86	941.96	3,506.64	2,425.84	3,033.01
4	Exceptional items						
5	<b>Total Profit / (Loss) Before Tax</b>	<b>1,816.78</b>	<b>2,200.86</b>	<b>941.96</b>	<b>3,506.64</b>	<b>2,425.84</b>	<b>3,033.01</b>
6	<b>Tax Expense</b>						
	Current tax	475.81	439.00	273.00	914.81	693.00	831.00
	Deferred tax	21.47	128.68	(32.98)	13.83	(80.54)	91.98
	Short/(excess) tax provision of earlier years	1.54	-	-	1.54	-	(175.64)
	<b>Total Tax Expenses</b>	<b>498.82</b>	<b>567.68</b>	<b>240.02</b>	<b>930.18</b>	<b>612.46</b>	<b>747.34</b>
7	<b>Net Profit / (Loss) for the Period from Continuing Operations</b>	<b>1,317.96</b>	<b>1,633.18</b>	<b>701.94</b>	<b>2,576.46</b>	<b>1,813.38</b>	<b>2,285.67</b>
8	<b>Total Profit / (Loss) for Period</b>	<b>1,317.96</b>	<b>1,633.18</b>	<b>701.94</b>	<b>2,576.46</b>	<b>1,813.38</b>	<b>2,285.67</b>
9	<b>Other Comprehensive Income (OCI)</b>						
	Items that will not be reclassified to profit or loss	-	-	-	-	(213.60)	(264.54)
	Less: Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	53.76	66.58
	Other Comprehensive Income / Loss (net of taxes)	-	-	-	-	(159.84)	(197.96)
10	<b>Total Comprehensive Income</b>	<b>1,317.96</b>	<b>1,633.18</b>	<b>701.94</b>	<b>2,576.46</b>	<b>1,653.54</b>	<b>2,087.71</b>
11	<b>Reserves</b>						<b>8,807.09</b>
12	<b>Details of Equity Share Capital</b>						
	Paid-up equity share capital	778.30	778.30	778.30	778.30	778.30	778.30
	Face value of equity share capital (Rs.)	1.00	1.00	1.00	1.00	1.00	1.00
13	<b>Earning per equity share</b>						
i	Basic earnings/(loss) per share from continuing and discontinued operations	1.69	2.10	0.90	3.31	2.33	2.94
ii	Diluted earnings/(loss) per share from continuing and discontinued operations	1.69	2.10	0.90	3.31	2.33	2.94

For GUFIC BIOSCIENCES LIMITED

**PRANAV CHOKSI**  
DIN:00001731



For identification purposes only.





**Notes:**

1. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards), Rules, 2015 (Ind AS) as amended, prescribed under section 133 of companies Act, 2013, read with rules issued thereunder.
2. The above results for the quarter and nine months ended December 31, 2020 have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on February 08, 2021. The Statutory Auditors have carried out limited review of the results for quarter and nine months ended December 31, 2020.
3. The Company's business activity falls within a single operating segment i.e. Pharmaceuticals.
4. The Board of Directors of the Company at its Board meeting held on March 25, 2019 approved the Scheme of Amalgamation of Gufic Lifesciences Private Limited ("Transferor Company") with the Company and their respective shareholders and creditors ("Scheme"), subject to sanction of the regulatory authorities. The BSE Limited and National Stock Exchange of India Limited vide its letters dated April 15, 2020 issued "Observation Letter" approving the said Scheme, subject to compliance of the said letters. The Transferor Company and the Company had filed the application for approval of the Scheme before the Hon'ble National Company Law Tribunal ("NCLT"), Ahmedabad Bench and NCLT, Mumbai Bench respectively. The said Scheme have been sanctioned by NCLT, Ahmedabad bench on December 31, 2020, subject to the sanction of the Scheme by NCLT, Mumbai bench. The final hearing date for the approval of the Scheme has been fixed on February 11, 2021 by the NCLT, Mumbai bench.
5. Previous year figures have been regrouped / reclassified, wherever necessary.

*For identification purpose only.*

**For GUFIC BIOSCIENCES LIMITED**

*[Signature]*  
**Director**

**PRANAV CHOKSI**  
**DIN: 00001731**





# MITTAL AGARWAL & COMPANY

## CHARTERED ACCOUNTANTS

Limited Review Report on the Unaudited Quarterly and Year to Date Financial Results of the Company Pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended

Review Report to  
The Board of Directors  
Gufic Biosciences Limited

- 1) We have reviewed the accompanying statement of Unaudited Financial Results of **Gufic Biosciences Limited** (the "Company") for the quarter ended 31 December 2020 and year to date results for the period from 1 April 2020 to 31 December 2020 (the "Statement").
- 2) This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
- 3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit, and accordingly, we do not express an audit opinion.
- 4) Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 5) The comparative financial information of the Company for corresponding quarter ended 31 December 2019 and year to date 31 December 2019 were reviewed by the predecessor auditor and the financial statements of the Company for the year ended 31 March 2020 were audited by the predecessor auditor who expressed an unmodified opinion on the financial information for the quarter ended and year to date 31 December 2019 on 13 February 2020 and unmodified opinion on financial statement for the year ended 31 March 2020 on 31 July 2020.

For Mittal Agarwal & Company  
Chartered Accountants  
(Firm Registration No. 131025W)



*Piyush Agarwal*

Piyush Agarwal  
Partner  
Membership No. 135505

Place: Mumbai  
Dated: 08/02/2021  
UDIN: 21135505AAAACL1970